NASDAQ:KURA
Kura Oncology Stock News
$21.01
+0.380 (+1.84%)
At Close: May 06, 2024
Kura Oncology to Participate in Two Upcoming Investor Conferences
07:30am, Tuesday, 07'th Sep 2021
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2021 Results - Earnings Call Transcript
04:21pm, Saturday, 07'th Aug 2021
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2021 Results - Earnings Call Transcript
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
07:30am, Wednesday, 04'th Aug 2021
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to Report Second Quarter 2021 Financial Results
04:05pm, Thursday, 29'th Jul 2021
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors –
Kura Oncology to Participate in JMP Securities Life Sciences Conference
07:30am, Thursday, 10'th Jun 2021
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Appoints Carol Schafer to Board of Directors
07:30am, Friday, 04'th Jun 2021
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
20 Short Ideas With Super-Weak Momentum
10:39am, Monday, 31'st May 2021
Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since
Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
07:30am, Thursday, 13'th May 2021
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2021 Results - Earnings Call Transcript
09:47am, Sunday, 09'th May 2021
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2021 Results - Earnings Call Transcript
Kura Oncology to Report First Quarter 2021 Financial Results
07:30am, Thursday, 29'th Apr 2021
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
04:08pm, Monday, 22'nd Mar 2021
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2020 Results - Earnings Call Transcript
01:43pm, Wednesday, 24'th Feb 2021
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2020 Results - Earnings Call Transcript
Kura Oncology Receives FDA Breakthrough Therapy Tag For Tipifarnib In Head & Neck Cancer
09:12am, Wednesday, 24'th Feb 2021
The FDA has designated Breakthrough Therapy status to Kura Oncology Inc's (NASDAQ: KURA) tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
07:20am, Wednesday, 24'th Feb 2021
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –
